Selegiline as immunostimulant — a novel mechanism of action?
In clinical studies the MAO-B inhibitor selegiline appears to slow the progression of neurological deficits in Parkinson’s disease (PD) and the cognitive decline in Alzheimer’s disease (AD). The mechanisms of action remain unclear. Several lines of evidence indicate an immune-mediated pathophysiology of PD and AD. According to animal trials, selegiline increases the survival rate of immune suppressed mice. Stimulation of the immune response to bacterial or viral infection or in chronic inflammatory processes is managed by an increased synthesis of the cytokines interleukin-lß (IL-1ß) and subsequent interleukin-6 (IL-6). Outcome of viral or bacterial infections in the brain highly correlates with levels of the cytotoxic cytokine tumor-necrosis-factor-alpha (TNF). The aim of our study was to characterize the influence of selegiline on the biosynthesis of IL-1ß, IL-6 and TNF in human peripheral blood mononuculear cells (PBMC) from healthy blood donors. After isolation and washing PBMC were cultured without and with selegiline in three different concentrations (0.01 μmol/l, 0.001 μmol/l, 0.0001 μmol/l) in a humidified atmosphere (7% CO2). Then cultures were centrifuged and supernatants were collected for IL-1ß, IL-6 and TNF ELISAassays. Treatment of cultured PBMC with various concentrations induced an increased synthesis of IL-lß (ANOVA F = 9.703, p = 0.0007), IL-6 (ANOVA F = 20.648, p = 0.0001) and a reduced production of TNF (ANOVA F = 3.770, p = 0.040). These results indicate, that the influence of selegiline on the cytokine biosynthesis may also contribute to its putative neuroprotective properties.
KeywordsHealthy Blood Donor Human Peripheral Blood Leukocyte Septal Cholinergic Neuron Chronic Relapse Experimental Autoimmune Encephalomyelitis Organum Vasculosum Lamina Terminalis
Unable to display preview. Download preview PDF.
- Brosnan CF, Selmaj K, Raine CS (1988) Hypothesis: a role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis. J Neuro-immunol 18: 87–94Google Scholar
- Cacabelos R, Barquero M, Garcia P, Alvarez XA, Varela de Seijas E (1991) Cerebrospinal fluid interleukin-1ß (IL-1ß) in Alzheimer’s disease and neurological disorders. Meth Find Exp Clin Pharmacol 13: 455–458Google Scholar
- Freisleben HJ, Lehr F, Fuchs J (1994) Lifespan of immunosuppressed NMRI-mice is increased by deprenyl. J Neural Transm [Suppl] 41: 231–236Google Scholar
- Gottschall PE, Komaki G, Arimura A (1991) Interleukin-1ß activation of the central nervous system. In: Rothwell N, Dantzer R (eds) Interleukin in the brain. Pergamon Press, Oxford, pp 27–49Google Scholar
- Kuhn W, Müller Th (1995) Neuroimmune mechanisms in Parkinson’s disease. J Neural Transm [Suppl] 46: 217–228Google Scholar
- Wollmann EE, Kopmels B, Bakalian A, Delhaye-Bouchard N, Fradelizi D, Mariani J (1992) Cytokines and neuronal degeneration. In: Rothwell N, Dantzer R (eds) Interleukin in the brain. Pergamon Press, Oxford, pp 187–203Google Scholar